No Data
Walvax Biotechnology (300142.SZ): The mRNA vaccine products under development primarily focus on preventing infectious diseases.
On December 26th, Gelonghui reported that Walvax Biotechnology (300142.SZ) recently stated during an investor relations activity that the current main research areas of mRNA vaccine development are infectious diseases and cancer, and that it is beginning to explore the shift from preventive products to therapeutic products. Since its establishment, the company has remained focused on the research and production of innovative blockbuster vaccines, with its mRNA vaccine products primarily aimed at preventing infectious diseases. The company will closely monitor the application of new technologies in innovative fields like cancer and the development of related products.
Walvax Biotechnology (300142.SZ): Currently engaged in the clinical development plan for the 9-valent HPV vaccine product, maintaining close communication with the CDE.
On December 26, Gelonghui reported that Walvax Biotechnology (300142.SZ) recently stated in an investor relations activity that the work for its subsidiary in Shanghai, Ze Run, for the phase III clinical study of the 9-valent HPV vaccine is progressing continuously. Currently, the phase III clinical trial comparing the immunogenicity of this vaccine with similar vaccines is in the data statistics analysis and clinical research report writing phase. The company is actively maintaining close communication with CDE, striving to promote the clinical research of protective efficacy with the optimal strategy based on the clinical development plan for the 9-valent HPV vaccine product.
Walvax Biotechnology (SZSE:300142) Investors Are Sitting on a Loss of 78% If They Invested Three Years Ago
Walvax Biotechnology Gets China Clinical Trial Approval for Anti-Tetanus Shot
Walvax Biotechnology Co., Ltd. (SZSE:300142) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Walvax biotechnology (300142.SZ): Recently conducting statistical analysis on the booster immunization stage data for infants and young children.
On November 20, Gelonghui reported that walvax biotechnology (300142.SZ) stated on the investor interaction platform that the ACYW135 group meningococcal polysaccharide conjugate vaccine developed by the company is currently in the III phase of clinical trials, and recent statistical analysis of the booster immunization phase data for infants and young children is being conducted.
There's Reason For Concern Over Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Price
No Data
